UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse

PloS one, 2011-02, Vol.6 (2), p.e16733

2011

Volltextzugriff (PDF)

Defining the catalytic activity of nanoceria in the P23H-1 rat, a photoreceptor degeneration model

PloS one, 2015-03, Vol.10 (3), p.e0121977-e0121977

2015

Volltextzugriff (PDF)

Intestine-enriched apolipoprotein b orthologs are required for stem cell progeny differentiation and regeneration in planarians

Nature communications, 2022-07, Vol.13 (1), p.3803-3803, Article 3803

2022

Volltextzugriff (PDF)

Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection

PloS one, 2013-03, Vol.8 (3), p.e58431

2013

Volltextzugriff (PDF)

Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways

Neurobiology of disease, 2011-06, Vol.42 (3), p.514-523

2011

Volltextzugriff (PDF)

Defining retinal progenitor cell competence in Xenopus laevis by clonal analysis

Development (Cambridge), 2009-05, Vol.136 (10), p.1707-1715

2009

Volltextzugriff (PDF)

Timing and topography of cell genesis in the rat retina

Journal of comparative neurology (1911), 2004-06, Vol.474 (2), p.304-324

2004

Volltextzugriff (PDF)

Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: A population-based study

Epilepsy research, 2011-06, Vol.95 (1), p.110-118

2011

Volltextzugriff (PDF)

Correction: Catalytic Nanoceria Are Preferentially Retained in the Rat Retina and Are Not Cytotoxic after Intravitreal Injection

PloS one, 2013-09, Vol.8 (9)

2013

Volltextzugriff (PDF)

Temporal Distribution Patterns of Alexa Fluor 647-Conjugated CeNPs in the Mouse Retina After a Single Intravitreal Injection

Advances in experimental medicine and biology, 2019, Vol.1185, p.125-130

2019

Volltextzugriff (PDF)

Nanoceria as bona fide catalytic antioxidants in medicine: what we know and what we want to know

Advances in experimental medicine and biology, 2014, Vol.801, p.821

2014

Volltextzugriff (PDF)

Zebrafish Lmx1b.1 and Lmx1b.2 are required for maintenance of the isthmic organizer

Development (Cambridge), 2005-07, Vol.132 (14), p.3163-3173

2005

Volltextzugriff (PDF)

MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion‐dependent thalassemia: An algorithm to guide clinical use when availability is limited

American journal of hematology, 2018-06, Vol.93 (6), p.E135-E137

2018

Volltextzugriff (PDF)

What predicts enduring intractability in children who appear medically intractable in the first 2 years after diagnosis?

Epilepsia (Copenhagen), 2013-06, Vol.54 (6), p.1056-1064

2013

Volltextzugriff (PDF)

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD‐ON DANICOPAN VS PLACEBO

HemaSphere, 2023-08, Vol.7 (S3), p.e777903c-n/a

2023

Volltextzugriff (PDF)

Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients

Blood, 2022-11, Vol.140 (Supplement 1), p.8658-8659

2022

Volltextzugriff (PDF)

12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Blood, 2021-11, Vol.138 (Supplement 1), p.2173-2173

2021

Volltextzugriff (PDF)

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Blood, 2021-11, Vol.138 (Supplement 1), p.345-345

2021

Volltextzugriff (PDF)

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.5803-5804

2022

Volltextzugriff (PDF)

Case Series of Primary Breast Diffuse Large B-Cll Lymphoma in Ampang Hospital, Malaysia

Blood, 2012-11, Vol.120 (21), p.5113-5113

2012

Volltextzugriff (PDF)

Risk Factors and Outcome of COVID-19 Infection in Haematological Patients : A Multicenter Retrospective Analysis in Malaysia

Blood, 2022-11, Vol.140 (Supplement 1), p.13232-13233

2022

Volltextzugriff (PDF)

Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

Blood, 2020-11, Vol.136 (Supplement 1), p.37-38

2020

Volltextzugriff (PDF)

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Blood, 2021-11, Vol.138 (Supplement 1), p.695-695

2021

Volltextzugriff (PDF)

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Blood, 2019-11, Vol.134 (Supplement_1), p.952-952

2019

Volltextzugriff (PDF)

1 – 25 von 204

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(189)
Mit Volltextzugriff
(180)

Publikationsform

Sprache

Englisch
(204)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 7 Tagen
(1)
... seit 30 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Nanoceria inhibit the development and promote the regression of pathologic retinal neovascularization in the Vldlr knockout mouse

Defining the catalytic activity of nanoceria in the P23H-1 rat, a photoreceptor degeneration model

Intestine-enriched apolipoprotein b orthologs are required for stem cell progeny differentiation and regeneration in planarians

Catalytic nanoceria are preferentially retained in the rat retina and are not cytotoxic after intravitreal injection

Nanoceria extend photoreceptor cell lifespan in tubby mice by modulation of apoptosis/survival signaling pathways

Defining retinal progenitor cell competence in Xenopus laevis by clonal analysis

Timing and topography of cell genesis in the rat retina

Incidence and classification of new-onset epilepsy and epilepsy syndromes in children in Olmsted County, Minnesota from 1980 to 2004: A population-based study

Correction: Catalytic Nanoceria Are Preferentially Retained in the Rat Retina and Are Not Cytotoxic after Intravitreal Injection

Temporal Distribution Patterns of Alexa Fluor 647-Conjugated CeNPs in the Mouse Retina After a Single Intravitreal Injection

Nanoceria as bona fide catalytic antioxidants in medicine: what we know and what we want to know

Zebrafish Lmx1b.1 and Lmx1b.2 are required for maintenance of the isthmic organizer

MRI for the diagnosis of cardiac and liver iron overload in patients with transfusion‐dependent thalassemia: An algorithm to guide clinical use when availability is limited

What predicts enduring intractability in children who appear medically intractable in the first 2 years after diagnosis?

P771: PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AND CLINICALLY SIGNIFICANT EXTRAVASCULAR HEMOLYSIS ON RAVULIZUMAB/ECULIZUMAB SHOWED HEMOGLOBIN RESPONSE SUPERIORITY WITH ADD‐ON DANICOPAN VS PLACEBO

P774: SUBSTANTIAL INCREASES IN PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH) RED BLOOD CELL CLONE SIZE WITH ORAL IPTACOPAN MONOTHERAPY CONFIRMS CONTROL OF HEMOLYSIS IN COMPLEMENT INHIBITOR‐NAÏVE PNH PATIENTS

Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients

12-Month Analysis of a Phase 2 Study of Iptacopan (LNP023) Monotherapy for Paroxysmal Nocturnal Hemoglobinuria

Surgeries and Diagnostic Procedures in Hemophilia Patients on Concizumab Prophylaxis: Results from the Phase 2 Explorer4 and Explorer5 Trials

Dose-Exposure-Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy

Case Series of Primary Breast Diffuse Large B-Cll Lymphoma in Ampang Hospital, Malaysia

Risk Factors and Outcome of COVID-19 Infection in Haematological Patients : A Multicenter Retrospective Analysis in Malaysia

Efficacy and Safety of Concomitant Use of Ravulizumab and IST in Patients with Paroxysmal Nocturnal Hemoglobinuria up to 52 Weeks

Gilteritinib Versus Salvage Chemotherapy for Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Phase 3, Randomized, Multicenter, Open-Label Trial in Asia

Breakthrough Hemolysis in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Ravulizumab: Results of a 52-Week Extension from Two Phase 3 Studies

Suchergebnisse filtern